HRTX News and Press, Heron Therapeutics Inc. From 05/09/22

Heron Therapeutics press release (NASDAQ:HRTX): Q1 GAAP EPS of -$0.63 misses by $0.15. Revenue of $23.46M (+17.2% Y/Y) beats by $0.85M. For further details see: Heron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85M

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates PR Newswire - ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare a...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 PR Newswire SAN DIEGO , May 3, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives o...

Citing up to date short interest data as of Apr. 26, Cantor Fitgerald points out that the oncology-focused biopharmaceutical company Veru (NASDAQ:VERU) had the biggest jump in short interest under its coverage with a ~279% increase. Miami, Florida-based Veru (VERU) added more than 25% of valu...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this event. For further details see: Heron Therapeutics (HRTX) Presents At 21st Annual Needham Virtual Healthcare Conference - Slideshow

Referring to the most up-to-date market data as of Apr. 11, Cantor Fitzgerald has listed the biotech companies with the most notable changes in the short interest. The nano-cap commercial-stage pharma company, Clarus Therapeutics (CRXT) dominates the list with over ten times increase in short...

Heron Therapeutics Inc. (NASDAQ:HRTX) traded today at a new 52-week high of $42.80. Approximately 85.4 million shares have changed hands today, as compared to an average 30-day volume of 2.8 million shares. Based on a current price of $6.09, Heron Therapeutics Inc. is currently 0.7% abov...

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference PR Newswire SAN DIEGO , April 5, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of...